Xuan et al. [53] found that XRCC1 can increase the base repair ability and promote tumor resistance via the tumor drug resistance pathway, suggesting that variants in the DNA repair pathway may impact patient outcomes and treatment-related responses. This evidence concerns the gene XRCC1 and neoplasm.